Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis B Cortot

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Chest|October 22, 2017
Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free ApproachOlivier Le Rouzic, Nicolas Roche, Alexis B Cortot, et al.
Investigational New Drugs|April 5, 2020
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancerNobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, et al.
Histopathology|June 9, 2026
Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancerAlexis B Cortot, Romain Dubois, Valérie Grégoire, et al.
Oncoimmunology|July 3, 2024
<i>Faecalibaterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitorsMarius Bredon, Camille Danne, Hang Phuong Pham, et al.
Biorxiv : the Preprint Server for Biology|November 15, 2023
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulationCélia Guérin, Audrey Vinchent, Marie Fernandes, et al.
Molecular Oncology|February 21, 2025
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulationCélia Guérin, Audrey Vinchent, Marie Fernandes, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Nature|December 25, 2009
Novel mutant-selective EGFR kinase inhibitors against EGFR T790MWenjun Zhou, Dalia Ercan, Liang Chen, et al.
Journal of Comparative Effectiveness Research|January 21, 2025
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring <i>MET</i> exon 14 skipping treated with systemic therapyMichael Thomas, Petros Christopoulos, Wade T Iams, et al.
Oncotarget|December 30, 2017
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsSimon Baldacci, Julien Mazieres, Pascale Tomasini, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Chest|October 22, 2017
Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free ApproachOlivier Le Rouzic, Nicolas Roche, Alexis B Cortot, et al.
Investigational New Drugs|April 5, 2020
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancerNobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, et al.
Histopathology|June 9, 2026
Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancerAlexis B Cortot, Romain Dubois, Valérie Grégoire, et al.
Oncoimmunology|July 3, 2024
<i>Faecalibaterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitorsMarius Bredon, Camille Danne, Hang Phuong Pham, et al.
Biorxiv : the Preprint Server for Biology|November 15, 2023
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulationCélia Guérin, Audrey Vinchent, Marie Fernandes, et al.
Molecular Oncology|February 21, 2025
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulationCélia Guérin, Audrey Vinchent, Marie Fernandes, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Nature|December 25, 2009
Novel mutant-selective EGFR kinase inhibitors against EGFR T790MWenjun Zhou, Dalia Ercan, Liang Chen, et al.
Journal of Comparative Effectiveness Research|January 21, 2025
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring <i>MET</i> exon 14 skipping treated with systemic therapyMichael Thomas, Petros Christopoulos, Wade T Iams, et al.
Oncotarget|December 30, 2017
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsSimon Baldacci, Julien Mazieres, Pascale Tomasini, et al.
Pageof 8